TITLE

A Novel Cancer Testis Antigen, A-Kinase Anchor Protein 4 (AKAP4) Is a Potential Biomarker for Breast Cancer

AUTHOR(S)
Saini, Shikha; Jagadish, Nirmala; Gupta, Anju; Bhatnagar, Amar; Suri, Anil
PUB. DATE
February 2013
SOURCE
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Breast cancer is the second leading cause of cancer related deaths in women worldwide. Reports about the early diagnosis of breast cancer are suggestive of an improved clinical outcome and overall survival rate in cancer patients. Therefore, cancer screening biomarker for early detection and diagnosis is urgently required for timely treatment and better cancer management. In this context, we investigated an association of cancer testis antigen, A-Kinase anchor protein 4 (AKAP4) with breast carcinoma. Methodology/Findings: We first compared the AKAP4 gene and protein expression in four breast cancer cells (MCF7, MDA-MB-231, SK-BR3 and BT474) and normal human mammary epithelial cells. In addition, 91 clinical specimens of breast cancer patients of various histotypes including ductal carcinoma in situ, infiltrating ductal carcinoma and infiltrating lobular carcinoma and 83 available matched adjacent non-cancerous tissues were examined for AKAP4 gene and protein expression by employing in situ RNA hybridization and immunohistochemistry respectively. Humoral response against AKAP4 was also investigated in breast cancer patients employing ELISA. Our in vitro studies in all breast cancer cells revealed AKAP4 gene and protein expression whereas, normal human mammary epithelial cells failed to show any expression. Using in situ RNA hybridization and immunohistochemistry, 85% (77/91) tissue specimens irrespective of histotypes, stages and grades of breast cancer clinical specimens revealed AKAP4 gene and protein expression. However, matched adjacent non-cancerous tissues failed to display any AKAP4 gene and protein expression. Furthermore, humoral response was observed in 79% (72/91) of total breast cancer patients. Interestingly, we observed that 94% (72/77) of breast cancer patients found positive for AKAP4 protein expression generated humoral response against AKAP4 protein. Conclusions: Collectively, our data suggests that AKAP4 may be used as serum based diagnostic test for an early detection and diagnosis of breast cancer and may be a potential target for immunotherapeutic use.
ACCESSION #
87625200

 

Related Articles

  • Immune monitoring technology primer. Dobbin, Kevin K. // Journal for ImmunoTherapy of Cancer;10/20/2015, Vol. 3, p1 

    Background: Recent biotechnological developments have resulted in increasing interest in immunology biomarkers. These biomarkers have potential clinical utility in the near future as predictors of treatment response. Hence, clinical validation of these predictive markers is critical. Findings:...

  • Accumulation of an Endogenous Tryptophan-Derived Metabolite in Colorectal and Breast Cancers. Puccetti, Paolo; Fallarino, Francesca; Italiano, Antoine; Soubeyran, Isabelle; MacGrogan, Gaetan; Debled, Marc; Velasco, Valerie; Bodet, Dominique; Eimer, Sandrine; Veldhoen, Marc; Prendergast, Georges C.; Platten, Michael; Bessede, Alban; Guillemin, Gilles J. // PLoS ONE;Apr2015, Vol. 10 Issue 4, p1 

    Tumor immune escape mechanisms are being regarded as suitable targets for tumor therapy. Among these, tryptophan catabolism plays a central role in creating an immunosuppressive environment, leading to tolerance to potentially immunogenic tumor antigens. Tryptophan catabolism is initiated by...

  • Biclustering reveals breast cancer tumour subgroups with common clinical features and improves prediction of disease recurrence. Wang, Yi Kan; Print, Cristin G.; Crampin, Edmund J. // BMC Genomics;2013, Vol. 14 Issue 1, p1 

    Background: Many studies have revealed correlations between breast tumour phenotypes, variations in gene expression, and patient survival outcomes. The molecular heterogeneity between breast tumours revealed by these studies has allowed prediction of prognosis and has underpinned stratified...

  • Most Random Gene Expression Signatures Are Significantly Associated with Breast Cancer Outcome. Venet, David; Dumont, Jacques E.; Detours, Vincent // PLoS Computational Biology;Oct2011, Vol. 7 Issue 10, p1 

    Bridging the gap between animal or in vitro models and human disease is essential in medical research. Researchers often suggest that a biological mechanism is relevant to human cancer from the statistical association of a gene expression marker (a signature) of this mechanism, that was...

  • 6P INVESTIGATION OF THE HELICASE ANTIGEN (HAGE) AS IMMUNOTHERAPEUTIC TARGET FOR BREAST CANCER THERAPY. Nagarajan, D.; Pockley, G.; Rees, R.; McArdle, S. // Annals of Oncology;Nov2014, Vol. 25 Issue suppl_6, pvi3 

    Background: The delivery of specific immunotherapies for malignant tumours requires the identification of relevant tumour antigens and sequences from these which can be used to stimulate protective T cell-mediated immunity. HAGE (DDX43) is a cancer testis antigen belonging to the DEAD box family...

  • Gene silencing of A-kinase anchor protein 4 inhibits cervical cancer growth in vitro and in vivo. Saini, S.; Agarwal, S.; Sinha, A.; Verma, A.; Parashar, D.; Gupta, N.; Ansari, A. S.; Lohiya, N. Kumar; Jagadish, N.; Suri, A. // Cancer Gene Therapy;Jul2013, Vol. 20 Issue 7, p413 

    Earlier, we reported an association of A-kinase anchor protein 4 (AKAP4) expression in cervical cancer patient specimens, indicating its implications as an immunotherapeutic target. In this study, we investigated the possible role of AKAP4 in cervical carcinogenesis. AKAP4 messenger RNA and...

  • Increased levels of choline metabolites are an early marker of docetaxel treatment response in BRCA1-mutated mouse mammary tumors: an assessment by ex vivo proton magnetic resonance spectroscopy. van Asten, Jack J. A.; Vettukattil, Riyas; Buckle, Tessa; Rottenberg, Sven; van Leeuwen, Fijs; Bathen, Tone F.; Heerschap, Arend // Journal of Translational Medicine;2015, Vol. 13 Issue 1, p1 

    Background: Docetaxel is one of the most frequently used drugs to treat breast cancer. However, resistance or incomplete response to docetaxel is a major challenge. The aim of this study was to utilize MR metabolomics to identify potential biomarkers of docetaxel resistance in a mouse model for...

  • Immunotherapy with MVA-BN-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells. Mandl, Stefanie; Rountree, Ryan; Dalpozzo, Katie; Do, Lisa; Lombardo, John; Schoonmaker, Peter; Dirmeier, Ulrike; Steigerwald, Robin; Giffon, Thierry; Laus, Reiner; Delcayre, Alain // Cancer Immunology, Immunotherapy;Jan2012, Vol. 61 Issue 1, p19 

    MVA-BN-HER2 is a new candidate immunotherapy designed for the treatment of HER-2-positive breast cancer. Here, we demonstrate that a single treatment with MVA-BN-HER2 exerts potent anti-tumor efficacy in a murine model of experimental pulmonary metastasis. This anti-tumor efficacy occurred...

  • Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines. Bilusic, Marijo; Gulley, James // Cancer Immunology, Immunotherapy;Jan2012, Vol. 61 Issue 1, p109 

    Therapeutic cancer vaccines are an emerging and potentially effective treatment modality. Cancer vaccines are usually very well tolerated, with minimal toxicity compared with chemotherapy. Unlike conventional cytotoxic therapies, immunotherapy does not result in immediate tumor shrinkage but may...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics